Nov 18, 2021 / 08:00AM GMT
Maurice Thomas Raycroft - Jefferies LLC, Research Division - Equity Analyst
Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. It's with great pleasure that I'd like to welcome the Karyopharm team, including Richard Paulson, CEO; Mike Mason, CFO; and Jatin Shah, the CMO. Thanks for joining us today for our London conference.
Richard A. Paulson - Karyopharm Therapeutics Inc. - President, CEO & Director
Absolutely. Great to be here, Maury.
Questions and Answers:
Maurice Thomas Raycroft - Jefferies LLC, Research Division - Equity AnalystAnd we're going to do a fireside chat format. So maybe to start off, for those who may be new to the story, can you provide a 1-minute intro to Karyopharm?
Richard A. Paulson - Karyopharm Therapeutics Inc. - President, CEO & Director
Sure. I mean when you look at Karyopharm, we're still a young company. We are an innovation and science-based commercial-stage pharmaceutical company now that